Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor

Stock Track04-15

Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.

The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.

This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194083813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194083813","market":"nz","top_or_hot":-1,"title":"Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor","media":"Stock Track","content":"<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1194083813","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194083813","pubTimestamp":1776217187,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|Genfleet Therapeutics-B盘中大涨5.48%KRAS G12D抑制剂获突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194083813","isCrawlerRequest":true}